MARIA FERNANDA ABALEM DE SA CARRICONDO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Assessment of the outflow drainage system in AMD after multiple anti-VEGF intravitreous injections(2018) CARRICONDO, Pedro C.; ZACHARIAS, Leandro C.; RODRIGUES, Taurino; YAGAESHI, Larissa Y.; PIMENTEL, Sergio Luis G.; ABALEM, Maria Fernanda; MORAES, C. Gustavo De; SUSANNA, Remo- Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control(2019) MOTTA, Augusto A. L.; BONANOMI, Maria Teresa B. C.; FERRAZ, Daniel A.; PRETI, Rony C.; SOPHIE, Raafay; ABALEM, Maria F.; QUEIROZ, Marcia S.; PIMENTEL, Sergio L. G.; TAKAHASHI, Walter Y.; DAMICO, Francisco M.Aims: To analyze contrast sensitivity of intravitreal bevacizumab injections with optimizing glycemic control versus optimizing glycemic control (in combination with sham injections) in eyes with Diabetic Macular Edema (DME). Design: Prospective, interventional, masked, randomized controlled trial. Methods: Forty-one eyes of 34 patients with type 2 diabetes mellitus and DME with glycated hemoglobin (HbA1c) < 11% received either intravitreal bevacizumab injection (Group 1) or sham injection (Group 2) at 0 and 6 weeks along with optimizing glycemic control. Mean change in best-corrected visual acuity (BCVA), contrast sensitivity (CS), optical coherence tomography (OCT)-measured by central macular thickness (CMT) were compared and correlated at baseline, 2, 6 and 12 weeks. Results: The study showed a mean CS improved in group 1 from 1.14 +/- 0.36 logCS to 1.32 +/- 0.24 logCS and also in group 2 from 1.11 +/- 0.29 logCS to 1.18 +/- 0.29 logCS at 12 weeks (P = 0.12). CS and CMT promptly decreased in group 1 compared to group 2 at 2 weeks (Delta CS = 0.15 +/- 0.25 vs. 0.03 +/- 0.15 logCS; P = 0.04; Delta CMT = 116 +/- 115 vs. 17 +/- 71 mu m; P = 0.01). There was a mean reduction of approximately 0.5% in HbA1c levels in both groups at 12 weeks (P = 0.002). Conclusion: The use of bevacizumab in combination with optimizing glycemic control results in earlier improvement of contrast sensitivity in type 2 diabetes patients with DME. However, the optimizing glycemic control itself has shown also to be effective at 12 weeks.
conferenceObject Enhanced Depth Image Optical Coherence Tomography (EDI-OCT) choroidal evaluation in patients with diabetes and correlation with retinal and kidney disease(2016) ABALEM, Maria Fernanda; PRETI, Rony Carlos; GARCIA, Rafael; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro C.; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.- Idiopathic Organ Transplant Chorioretinopathy after Liver Transplantation(2015) ABALEM, Maria Fernanda; CARRICONDO, Pedro Carlos; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter YukihikoIdiopathic organ transplant chorioretinopathy is a rare disease associated with kidney and heart transplantation. We present a case secondary to liver transplantation including its multimodal imaging, differential diagnosis, and physiopathology discussion.
- Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion(2019) HALL, Leangelo; FRIZZERA, Luma Paiva; COELHO, Laura Fernandes; CARRICONDO, Pedro Carlos; OYAMADA, Maria Kiyoko; PIMENTEL, Sergio Luis Gianotti; ABALEM, Maria FernandaBackgroundAlthough previous studies have evaluated the effect of anti-VEGF therapies for central retinal vein occlusion (CRVO) patients, the majority of previous studies have excluded or included a very small number of patients with ischemic CRVO (iCRVO). The aim of our study is to examine the effects of bevacizumab on macular edema secondary to ischemic central retinal vein occlusion, as well as the effects on central choroidal thickness and best-corrected visual acuity.MethodsIn this prospective, interventional case series, iCRVO was defined by the presence of >= 10 or more disc diameter areas of retinal nonperfusion by fluorescein angiography (FA) and by the presence of a b/a ratio less than 1.5 by full-field electroretinogram (ffERG). Nine eyes with iCRVO received monthly bevacizumab 0.5 mg injections at baseline and months 1 to 5 for a maximum of six injections. Main outcome measures were visual acuity (Snellen), central foveal thickness, and central choroidal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at baseline and at 6 month following initial intravitreal bevacizumab injection. Pairwise t-tests and the Wilcoxon signed-rank test were conducted to compare the outcome measures.ResultsAfter intravitreal administration of bevacizumab, there was a significant reduction of central foveal thickness from 858311 mu m at baseline to 243 +/- 106 mu m at the 6-month follow-up, as well as a significant reduction of central choroidal thickness from 282 +/- 38 mu m at baseline to 227 +/- 56 mu m at the 6-month follow-up (p=0.0006, p=0.0003 respectively). The visual acuity worsened from a median of 1.3 to 1.7 (p=0.02).ConclusionIn patients with iCRVO, intravitreal bevacizumab led to a reduction of central macular edema and central choroidal thickness, but a worsening of visual acuity. Intravitreal bevacizumab reduces macular edema but is not able to overcome the poor prognosis of iCRVO.
conferenceObject Correlation of Enhanced Depht Imaging Optical Coherence Tomography (EDI-OCT) choroidal findings and visual acuity in sickle cell disease(2016) CARRICONDO, Pedro C.; ABALEM, Maria Fernanda; BONANOMI, Maria Teresa B. C.; PRETI, Rony; PIMENTEL, Sergio Luis Gianotti; MONTEIRO, Mario L. R.; TAKAHASHI, Walter Y.conferenceObject Foveal choroidal thickness using spectral-domain optical coherence tomography in diabetic patients during the water-drinking test(2016) PRETI, Rony; ABALEM, Maria Fernanda; GARCIA, Rafael; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro C.; ZACHARIAS, Leandro C.; PIMENTEL, Sergio Luis Gianotti; SUSANNA, Remo; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.conferenceObject Retinal blood vessels diameters in unilateral ischemic central retinal vein occlusion using infrared imaging.(2016) GARCIA, Rafael; ABALEM, Maria Fernanda; PRETI, Rony; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro Carlos; ZACHARIAS, Leandro C.; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.- Choroidal and Retinal Abnormalities by Optical Coherence Tomography in Endogenous Cushing's Syndrome(2016) ABALEM, Maria Fernanda; MACHADO, Marcio Carlos; SANTOS, Helen Nazareth Veloso Dos; GARCIA, Rafael; HELAL JR., John; CARRICONDO, Pedro Carlos; PIMENTEL, Sergio Luis Gianotti; MONTEIRO, Mario Luiz Ribeiro; QIAN, Cynthia X.; BRONSTEIN, Marcello Delano; FRAGOSO, Maria Candida Villares BarissonContext: Cortisol has been suggested as a risk factor for choroidal thickening, which may lead to retinal changes. Objective: To compare choroidal thickness measurements using optical coherence tomography (OCT) in patients with endogenous active Cushings syndrome (CS) and to evaluate the occurrence of retinal abnormalities in the same group of patients. Design: Cross-sectional study. Setting: Outpatient clinic. Patients: Eleven female patients with CS in hypercortisolism state as determined by the presence of at least two abnormal measurements from urinary cortisol 24 h, no suppression of cortisol with low dose dexamethasone suppression test, and nocturnal salivary cortisol levels and 12 healthy controls. Methods: Choroidal and retinal morphology was assessed using OCT. Main outcome measures: Choroidal thickness measurements and the presence of retinal changes. Results: The mean subfoveal choroidal thickness was 372.96 +/- 73.14 m in the patients with CS and 255.63 +/- 50.70 mu m in the control group (p < 0.001). One patient (9.09%) presented with central serous chorioretinopathy and one patient (9.09%) with pachychoroid pigment epitheliopathy. Conclusion: Choroidal thickness is increased in the eyes of patients with active CS compared to healthy and matched control. Also, 18.18% of patients presented with macular changes, possibly secondary to choroidal thickening. While further studies are necessary to confirm our findings, excess corticosteroid levels seem to have a significant effect on the choroid and might be associated with secondary retinal diseases.
conferenceObject Short-Term Effects of Intravitreal Bevacizumab in Contrast Sensitivity of Patients with Diabetic Macular Edema and Optimizing Glycemic Control(2018) MOTTA, Augusto; BONANOMI, Maria Teresa B. C.; FERRAZ, Daniel Araujo; PRETI, Rony Carlos; SOPHIE, Raafay; MEDINA, Flavio Mac Cord; ABALEM, Maria Fernanda; QUEIROZ, Marcia; PIMENTEL, Sergio Luis G.; TAKAHASHI, Walter Yukihiko; DAMICO, Francisco Max